Entecavir for treatment of lamivudine-refractory chronic hepatitis B
- VernacularTitle:恩替卡韦治疗拉米夫定失效慢性乙型肝炎的临床观察
- Author:
Cheng WANG
;
Jinjun CHEN
;
Jian SUN
- Publication Type:Journal Article
- Keywords:
hepatitis B, chronic;
entecavir;
lamivudine;
antiviral agents
- From:
Medical Journal of Chinese People's Liberation Army
1983;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
12 months, baseline serum HBV DNA ≥104copies/ml) were prospectively followed. Virological and serologic responses and laboratory data of liver and renal function of each patient enrolled were monitored every three months. Entecavir resistant mutations were detected by direct sequencing of HBV reverse transcriptase region which was amplified by semi-nested polymerase chain reaction (PCR). HBV sequences of different genotypes obtained from GenBank were aligned to identify entecavir drug resistant substitutions. Results Of the 41 lamivudine refractory CHB patients who met the inclusion criteria, 16 patients (39%) achieved the point of undetectability in HBV DNA level (
